Watch Dr Jason Ray accept the research grant award and hear a bit about the project.
Migraine is the second leading cause of years lived with disability worldwide, affecting over 1.1 billion people. A new class of therapies, CGRP monoclonal antibodies, have proven effective in the prevention of migraine, and reducing its impact. The safety of these therapies long-term is therefore of material importance to clinicians and patients worldwide. Our preliminary research suggests that these medications may impact bone health.
With the support of the Brain Foundation, we will conduct a study to monitor the bone health of patients living with migraine who are commenced on these medications and compare this to patients who do not receive the medication. These results will be critical to informing clinicians worldwide on the safe use of these medications, any monitoring that may be required when taking the medication, or possibly any other benefits in taking the medication.
Thank you to the Brain Foundation, and their supporters for the opportunity to undertake this research into this critical area of need.